secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001213900-26-053369
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July
--------------------------------------------------------------------------------

- Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.
- Cash & investments $731.6M; excludes $351M net proceeds from April offering.
- R&D $35.7M, G&A $13.4M; total operating costs $49.9M.
- Phase 3 ZENITH-AD program in atopic dermatitis to initiate by July 2026.
- Closed public offerings raising $460M in Feb and $373.8M in April.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/0001213900-26-053369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/ea0289611-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-053369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer